NSE: DABUR | BSE: 500096

Expensive Performer

Download real time

522.05 -13.40 (-2.50%)

4.2M NSE+BSE Volume

NSE 22 Sep, 2025 3:31 PM (IST)

92,595.5

Market Cap

High in industry

0.6

Beta 1Year

Very Low volatility

Dabur India Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for DABUR, BSE:500096 Dabur India Ltd.

Dabur India Ltd.

21 Sep 2020, 12:00AM

522.05

-2.50%

DABUR INDIA LTD.

Buy: Dabur India Ltd.

Ventura

We initiate coverage on Dabur with a BUY for a price target of Rs.600 representing a potential appreciation of 22 % over the next 24 month from the CMP of Rs.490.

Dabur India Ltd. is trading below its 30 day SMA of 528.2

Dabur India Ltd.

19 Aug 2020

522.05

-2.50%

DABUR INDIA LTD.

Strategy Note: Dabur India Ltd.

Ventura

Quick Research Note

Number of FII/FPI investors decreased from 764 to 755 in Jun 2025 qtr

Dabur India Ltd.

04 Aug 2020

522.05

-2.50%

DABUR INDIA LTD

Hold: Dabur India Ltd.

Target

Geojit BNP Paribas

Dabur India Ltd (Dabur), a leading Indian FMCG company, is a world leader in Ayurveda with a portfolio of over 250 Herbal/Ayurvedic products. The company operates through Health Supplements, Digestives, Shampoos, Hair...

Number of FII/FPI investors decreased from 764 to 755 in Jun 2025 qtr

Dabur India Ltd.

31 Jul 2020

522.05

-2.50%

Dabur India

Hold: Dabur India Ltd.

Target

Arihant Capital

Dabur India earnings were below our estimates on all fronts as Covid-19 pandemic disrupted the business performance of the company. Profit for the quarter de-grew by 6.1%YoY/+21.0% QoQ to Rs 341 Cr during Q1FY21. Consolidated revenue stood at Rs 1,980 cr ,below our estimates Rs 2,209 registering a degrowth 12.9%YoY/+6.1%QoQ. Reported EBITDA de-grew by 9.0%YoY/+18.2%QoQ to Rs 416 Cr, below our estimate of Rs...

Dabur India Ltd.'s price crossed below 50Day SMA today

Dabur India Ltd.

31 Jul 2020

522.05

-2.50%

Dabur India

Buy: Dabur India Ltd.

Target

ICICI Securities Limited

The sanitisers & disinfectants space generated | 90 crore of sales in Q1 with several new products being launched. We believe the opportunity in immunity boosting products is more structural & leadership position in Chyawanprash & Honey is advantage for DIL. It gained market share in both segments by 600 bps & 300 bps, respectively, in Q1. Though growth rates in hygiene category may taper down in few quarters, the category is here to...

Number of FII/FPI investors decreased from 764 to 755 in Jun 2025 qtr

Dabur India Ltd.

30 Jul 2020

522.05

-2.50%

Q1FY21 Result Update - Scalability of new launches key; Hold

Hold: Dabur India Ltd.

Target

Prabhudas Lilladhar

July sales up 5-6%, no trade inventory build-up, MT/CSD under pressure. We are increasing FY21/22/23 EPS estimates of Dabur India by 8%/5.7%/4.3% following sales PAT beat in 1Q mainly led by Rs1.4bn incremental sales from new launches in Sanitizers and Healthcare products. Dabur is currently riding on rising consumer demand for immunity boosters and hygiene products...

Number of FII/FPI investors decreased from 764 to 755 in Jun 2025 qtr

Dabur India Ltd.

29 Jun 2020

522.05

-2.50%

Dabur - Significant transformations underway

Neutral: Dabur India Ltd.

Target

Motilal Oswal

Sales from new launches are targeted to reach ~5% of total sales in 2 years (from Mr. Malhotra believes that currently Dabur is less efficient than peers on several operating costs. is likely to see growth compared to the weak outlook 2-3 quarters ago due to the companys focus on Naturals and Ayurveda in current Dabur has introduced Sanitize brand. In a highly encouraging move, Mr. Malhotra stated that they aim to match or surpass the best domestic peers on the technology and analytics front in the next April and first half of May was a setback due to supply chain issues given the lack of clarity on classification of essential/non-essential items, particularly in the case of Ayurvedic products.

Dabur India Ltd. has an average target of 563.57 from 7 brokers.

Dabur India Ltd.

09 Jun 2020

522.05

-2.50%

Axis Alpha: Dabur India (BUY)

Buy: Dabur India Ltd.

Target

Axis Direct

We recommend a BUY on DABUR INDIA with a Target Price of Rs 504, an upside of 6% from CMP of Rs. 471 and Stop Loss Rs. 455.

Dabur India Ltd.'s price crossed below 50Day SMA today

Dabur India Ltd.

29 May 2020

522.05

-2.50%

Dabur India

Hold: Dabur India Ltd.

Target

Arihant Capital

Dabur India Q4FY20 earnings were below our projections with a miss in Revenue, EBITDA and PAT front. The company has reported a lower net profit at Rs 281 crore for the quarter under review as compared to Rs 370 crore for the same quarter in the previous year, impacted on account of lockdown during the second half of March 2020. Net sales dropped by 12.3% at Rs 1,865 crore for Q4 FY20 as compared to Rs 2,128 cr for the Q4FY19, EBITDA declined 23% YoY to Rs 352 crore for the Q4FY20 from Rs 457 crore for the Q3FY19 and EBITDA margin...

Dabur India Ltd. has an average target of 563.57 from 7 brokers.

Dabur India Ltd.

28 May 2020

522.05

-2.50%

Dabur India

Buy: Dabur India Ltd.

Target

ICICI Securities Limited

With increasing health consciousness, some products with immunity booster proposition like Chyawanprash, Honey & OTC products are gaining traction. Further, the company also launched five new products in the healthcare space along with immunity booster kit. DIL posted 400% surge in Chyawanprash demand & 80% growth in honey in the last few months inducing it to expand capacity of these products to meet the current demand. We believe health supplement would be driving the growth and could see structural demand improvement given increasing consumer...

Dabur India Ltd.'s price crossed below 50Day SMA today

Is Dabur India Ltd. worth buying?

671 Votes:

Buy 76.6%

Sell 12.22%

Hold 11.18%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf